Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
Portfolio Pulse from
Soleno Therapeutics has received FDA approval for VYKAT XR, an extended-release tablet designed to treat hyperphagia in adults and children 4 years and older with Prader-Willi syndrome. This marks the first approved therapy specifically addressing this condition, potentially representing a significant milestone for the company and patients.
March 26, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
FDA approval of VYKAT XR could drive investor confidence and potentially increase market valuation for Soleno Therapeutics.
FDA approval represents a significant milestone for Soleno, potentially opening new revenue streams and demonstrating the company's drug development capabilities in rare diseases.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100